145255-19-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Aminopyridine-2-carboxamide is used as a synthetic building block for the development of carboline analogs. These analogs have been identified as potent inhibitors of MAPKAP-K2, a protein kinase involved in various cellular processes. By inhibiting MAPKAP-K2, these carboline analogs can potentially be utilized in the treatment of diseases associated with the dysregulation of this protein kinase.
Additionally, 5-Aminopyridine-2-carboxamide may also be used as a starting material or intermediate in the synthesis of other bioactive compounds with potential therapeutic applications. Its unique chemical properties make it a valuable component in the development of novel drugs and pharmaceutical agents.
Used in Chemical Industry:
In the chemical industry, 5-Aminopyridine-2-carboxamide can be employed as a reactant in the synthesis of various organic compounds. Its reactivity and functional groups allow for a wide range of chemical reactions, enabling the creation of diverse products with different applications.
For example, it can be used in the synthesis of dyes, pigments, and other colorants, where its pyridine ring and amino group contribute to the desired color properties. Furthermore, it may also be utilized in the development of advanced materials, such as conductive polymers or sensors, where its electronic properties can be exploited for specific applications.

InChI:InChI=1/C6H7N3O/c7-4-1-2-5(6(8)10)9-3-4/h1-3H,7H2,(H2,8,10)

Upstream product

• 30651-24-2 5-nitropicolinic acid 
• 59290-34-5 5-nitropyridine-2-carboxamide 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 100367-55-3 5-nitropyridine-2-carbonitrile 
• 4487-59-6 2-bromo-5-nitropyridine 
• 55338-73-3 5-amino-2-cyanopyridine 

Relevant academic research and scientific papers

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and o edemas, and also ophthalmic disorders.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

[1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS

Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.

ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mekl, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2

Novel potassium channel openers: Synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds

This report describes the synthesis and pharmacological evaluation of a series of novel potassium channel openers related to the pinacidil-type compounds. Thioureas, cyanoguanidines, and pyridine N-oxides were systematically evaluated for their effects on both the inhibition of spontaneous mechanical activity in rat portal vein (in vitro) and their antihypertensive activity (in vivo), and the structure-activity relationship for this series of compounds was discussed. Good correlation between in vitro and iv antihypertensive activity was observed for these compounds. Among them, cyanoguanidines bearing a conformationally rigid unit such as a norbornyl group generally possessed potent activity in both in vitro and in vivo studies. Especially, N-(6-amino-3-pyridyl)-N'-cyano-N''-(1-methyl-2- norbornyl)guanidine (23d) was identified as a more potent potassium channel opener in vitro (EC100 = 3 x 10-8 M) than pinacidil (EC100 = 10-7 M).